CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 14 No. 8
Book Review 

Expert Consultations in Breast Cancer: Critical Pathways and Clinical Decision Making

Editors: William N. Hait, MD, PhD, David A. August, MD, and Bruce G. Haffty, MD
Publisher: Marcel Dekker AG, New York, New York
512 pages, illustrated
Price: $99.75

Reviewed by Kathy D. Miller, MD
Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana

| August 1, 2000

This book is the 17th volume in the Basic and Clinical Oncology series edited by Bruce D. Cheson, MD. Like other volumes in this series, Expert Consultations in Breast Cancer follows a unique format and seeks to integrate advances in the basic understanding of breast cancer with promising new therapies and changing health- care economics. The integration of these different perspectives provides both a conceptual and pragmatic framework for clinical decision-making.

The text begins with brief introductory chapters summarizing major topics, such as natural history, pathology, staging, surgery, radiation therapy, systemic treatment, and familial breast cancer. The review of the natural history of breast cancer provides a particularly important foundation, since virtually all clinical decisions rest on an accurate estimation of the risk of recurrence. The radiation therapy chapter provides a well-balanced discussion of the current controversy surrounding postmastectomy radiation. The review of inherited breast cancer susceptibility would be useful for both specialists and primary care physicians.

Although readers desiring a comprehensive review would be better directed to other texts, these introductory chapters provide a concise discussion of well-established data. Areas of controversy and ongoing research are cited, but the tone is generally conservative. For example, radiation therapy is recommended for all patients with ductal carcinoma in situ, with little consideration of substantial, albeit nonrandomized, data suggesting that some patients may be treated with wide excision alone. Furthermore, sentinel lymph node dissection is granted no role, while neoadjuvant therapy is recommended only for “patients desiring breast preservation, but presenting with lesions requiring mastectomy”—despite the results from five randomized trials showing equivalent or improved overall survival.

All texts suffer deficiencies stemming from the delay between initial writing and publication. For Expert Consultations in Breast Cancer, this problem is most obvious in the review of medical therapy for breast cancer, which focuses almost exclusively on the role of adjuvant treatment, along with useful descriptions of appropriate strategies based on patient and tumor characteristics. Important, but recently established, developments in the treatment of metastatic disease, including the use of bisphosphonates in patients with lytic bone lesions and the use of trastuzumab(Drug information on trastuzumab) (Herceptin) in patients with HER2-overexpressing tumors, are notably absent.

Part II showcases a series of clinical pathways that guide clinical decision-making. When describing these pathways, the authors intentionally avoid recommending specific chemotherapeutic regimens or surgical procedures, focusing instead on presenting a conceptual framework for the evaluation and treatment of patients in specific clinical situations. The pathways strive to be (and succeed in being) evidence based whenever possible. When evidence is lacking, a consensus of expert opinion is substituted, and evidence is clearly distinguished from opinion.

Part III—the longest section and perhaps the most unique portion of this text—features a series of case presentations accompanied by discussions by noted breast cancer experts. The case presentations follow the format of the pathways, and illustrate their practical application and usefulness. Additional presentations highlight unique situations that are not easily addressed within the context of the pathways.

A total of 31 situations cover the evaluation of nonpalpable breast lesions or nipple discharge, with discussions by radiologists and surgeons. Suggested plans are well supported and referenced, with excellent reviews of the diagnostic accuracy of nonsurgical methods. Eleven presentations review the challenges involved in the treatment of in situ disease, including incidentally discovered ductal carcinoma in situ and patients with microinvasive foci.

Several areas of controversy are evident in the 17 presentations that relate to the local treatment of invasive breast cancer. Specific situations include the role of a radiation “boost” to the tumor bed; the need for axillary dissection in elderly patients with small, good-prognosis tumors; and the problems involved in irradiating large, pendulous breasts. Brachytherapy is reviewed as an alternative to traditional external-beam radiation in one case presentation.

A total of 29 cases review systemic therapy for patients without overt metastatic disease, and, in keeping with the organization of the pathways, are segregated into node-negative, node-positive, nodal status unknown, and locally advanced categories. Here, specific chemotherapy regimens are recommended (or at least suggested), with reference to appropriate clinical trials. Consideration of the subtle differences in patient circumstances, including age, comorbidities, and patient preference, is an underlying theme of many of the discussions.

The topic of patients with recurrent disease is addressed with 29 case studies; local and systemic recurrences are considered separately. In general, although specific regimens are avoided, important distinctions are made between symptomatic and asymptomatic patients and those with visceral, as opposed to bone or soft-tissue, disease. Discussions of the utility (or lack thereof) of serum tumor markers are particularly helpful.

The final cases focus on topics, which, although not exceedingly rare, do not fit easily into the clinical pathways. Included are discussions of male breast cancer, Paget’s disease, the pregnant patient, paraneoplastic syndromes, and meningeal carcinomatosis. Complications of treatment, such as lymphedema and menopausal symptoms, are also considered.

Much redundancy can be found in the case presentations and accompanying discussions—at times, with conflicting opinions and recommendations. Although the editors do offer occasional comments or additional data for clarity, the disparate opinions may be disconcerting to the novice reader.

For the experienced clinician, however, these differences may have quite a contrary effect: They may serve to highlight areas of controversy and lively debate, providing the more advanced practitioner access to opinions from some of the leaders in the field. Furthermore, this section substantiates the need for clinical judgment and decision-making that integrates the most advanced basic science and clinical knowledge with the practical constraints of the clinic and health-care system—exactly the goal the editors set out to achieve.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy